Oxabicycloheptanes for Modulation of Immune Response
AssigneesLixte Biotechnology, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsJohn S. Kovach, Zhengping Zhuang, Sze Chun Winson Ho, Herui Wang, Rongze Lu
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor.
Claims49
A method of treating a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor in combination with an effective amount of a checkpoint inhibitor, wherein the amounts when taken together are effective to treat the subject.
A method of treating a subject afflicted with cancer and receiving a checkpoint inhibitor comprising administering to the subject of an amount of PP2A inhibitor effective to enhance treatment relative to the checkpoint inhibitor alone.
A method of treating a tumor or cancer in a subject comprising administering to the subject an effective amount of a PP2A inhibitor in combination with an effective amount of a checkpoint inhibitor, wherein the amounts when taken together are effective to treat the tumor or cancer.
A method of increasing a T-cell response to cancer cells in a subject afflicted with cancer comprising administering to the subject an amount of a PP2A inhibitor in combination with an effective amount of a checkpoint inhibitor effective to increase the T-cell response to the cancer cells.
A method of increasing T cell activation in a subject afflicted with cancer comprising administering to the subject an effective amount of a PP2A inhibitor in combination with an effective amount of a checkpoint inhibitor so as to thereby increase the T cell activation.
A method of inhibiting the function of a CTLA-4 in T cells comprising administering to the T cells a PP2A inhibitor so as to thereby inhibit the function of the CTLA-4.
A method of inhibiting the PD-1:PD-L1 interaction in T cells comprising administering to the T cells a PP2A inhibitor so as to thereby inhibit the interaction of PD-1:PD-L1.
Dependencies are inferred from the claim text.